ESG Report 2025

2 Chairman's Statement .1 02 Annual Performance Review As time moves forward and a new chapter unfolds, The United Laboratories entered 2025 with an unwavering commitment to its tenet of making life more valuable. Together with partners from all sectors, we continued to move steadily forward on the broad path of pharmaceutical innovation. Against the backdrop of the continued deepening of reforms in the medical and healthcare system, we have consistently adhered to the R&D philosophy of “Pragmatic and Rigorous, Scientific and Truth-seeking, Future-focused and Innovative”. Supported by the development of a high-calibre talent pipeline, we continued to increase investment in research and development, drive breakthroughs in key technologies and accelerate product iteration and upgrading. Backed by a scientific and efficient management system, we continuously optimised product and service quality and, with a spirit of pursuing perfection, guided the Company towards a new journey of high-quality and sustainable development. In terms of business layout, The United Laboratories continued to strengthen its presence in the core areas of pharmaceutical R&D, production and sales. Our product portfolio covers finished products, bulk medicine and intermediate products, veterinary drugs, pharmaceutical capsules and medical devices, forming a diversified, coordinated and well-structured product system. Guided by the goal of meeting people's healthcare needs, we closely track global frontiers in new drug R&D, focus on clinical value and differentiation strategies, and make forward-looking investments in innovative drugs and high-barrier complex preparations. Through continuous product innovation and quality enhancement, we contribute to building a stronger health protection barrier for the wider population. To further respond to the “Healthy China” strategy, we continued to enhance the accessibility and affordability of pharmaceutical products. In light of regional differences across overseas markets, we adopted locally adapted and equitable pricing strategies to ensure that high- quality medicines can benefit more people and help narrow disparities in global healthcare resources. At the same time, we actively expanded our international business footprint, promoted broader coverage of products included in the National Medical Insurance List and the National Essential Drugs List, and participated extensively in the National Centralised Procurement Scheme for Pharmaceutical Products, thereby effectively reducing patients' medication burden. Through organising and participating in high-level academic exchanges, we remained committed to advancing and sharing progress in global healthcare. In response to the profound impact of global climate change, we proactively incorporated climate risk response and opportunity identification into our strategic vision. We actively identified climate-related risks and opportunities across our production and operations as well as our value chain, promoted energy conservation, emission reduction and optimisation of the energy mix, and explored application scenarios for low-carbon technologies in the pharmaceutical sector. We also sought breakthroughs in green manufacturing and the circular economy, with a view to transforming climate challenges into new drivers of innovation-led development. Talent is the most valuable asset of the enterprise. The United Laboratories has always adhered to a people-oriented development philosophy. On the basis of safeguarding employee rights, interests and safety, we have established diversified and multi-level training and development systems to help employees enhance their professional competence and overall capabilities, thereby achieving resonance between individual growth and corporate development. We attach great importance to the physical and mental well-being of our employees. Through a wide range of cultural activities, we foster a harmonious and supportive working environment and strengthen team cohesion and employees' sense of belonging. Meanwhile, we uphold the business principle of “Friendship, Equality, and Mutual Development”, continue to improve supply chain management, strengthen information security and integrity governance, and consolidate the foundation for the Group's steady development. With responsibility on our shoulders, we continue to move forward without pause. The United Laboratories actively fulfils its social responsibilities by continuing to engage in diverse areas including chronic disease prevention and treatment, industrial assistance, educational support, disaster relief and pet welfare, while encouraging employees to participate in volunteer services and convey the warmth of the enterprise. Since the launch of the “Filial Piety Swallows” Charity Project, we have continued to promote and deepen the initiative. As at the end of the reporting period, over 100 activities had been carried out cumulatively, benefiting approximately 8,400 person-times in total, demonstrating our commitment as a responsible corporate citizen through practical actions. Looking ahead to 2026, The United Laboratories will embrace a new chapter of development. We will respond to industry transformation with an open and inclusive mindset and continue to consolidate our core competitiveness in innovative drugs and high-barrier complex preparations. We will fully integrate ESG concepts into our corporate strategy and operational practices and comprehensively enhance our sustainable development capabilities through the deep application of digital and intelligent technologies. While providing higher-quality pharmaceutical products and services, we will actively practise the concept of green and low-carbon development and build a diversified and mutually beneficial development platform. Leveraging our corporate influence as a bridge, we are willing to work hand in hand with our partners to build a sustainable industry ecosystem and inject stronger strength into the realisation of the “Healthy China” strategy. Chairman Tsoi Hoi Shan 2 2025 Environmental, Social and Governance Report The United Laboratories International Holdings Limited